Andropause: knowledge and awareness among primary care physicians in Victoria, BC, Canada.
The causes, symptoms and treatment options for andropause have been well documented; however, not enough is known about the primary care physicians' (PCPs) knowledge in this therapeutic area. This study assesses the PCPs' awareness and knowledge of andropause in Victoria, British Columbia, Canada.


METHODS
Self-administered questionnaires were developed for family physicians and general practitioners. Each questionnaire included questions in three domains: 1) General knowledge, beliefs and exposure; 2) Knowledge of diagnostic and treatment options and; 3) General demographics.


RESULTS
A very high percentage of PCPs had heard of andropause (96.3%). Of the physicians who completed the survey, 92.6% agreed that men experience something similar to women's menopause when they age and 98.0% agreed that andropause is associated with an increased risk of osteoporosis. Almost all PCPs (91.5%) agreed that prostate cancer is a contraindication to treatment while around one-third (33.9%) agreed that breast cancer was a contraindication. Slightly more than half of physicians (57.4%) felt that they encountered obstacles to their investigation of andropause with the most prevalent complaint being a lack of access to education resources. There is a need for improved continuing medical education (CME) programmes in the Greater Victoria region to give PCPs the skills to diagnose and manage andropause with confidence.
Pommerville
Peter J
PJ
Can-Med Clinical Research Inc., Victoria, BC, Canada. ppomm@pommerville-urology.com
Zakus
Paul
P
D000328:Adult; D047649:Andropause / Q000187:drug effects / Q000502:physiology; D001364:Awareness; D001955:British Columbia; D005260:Female; D007722:Health Knowledge, Attitudes, Practice; D020249:Hormone Replacement Therapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D010821:Physicians, Family / Q000193:education; D011795:Surveys and Questionnaires; D013739:Testosterone / Q000008:administration & dosage / Q000627:therapeutic use*
D013739:Testosterone